Citigroup’s Axsome Therapeutics AXSM Stock Holding History

Citigroup’s Portfolio AXSM Stock Details AXSM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-25,000	Closed	-$2.25M	–	5832
2024 Q3	$2.25M	Buy	+25,000	New	+$2.18M	﹤0.01%	2571
2023 Q4	–	Sell	-27,400	Closed	-$1.91M	–	5697
2023 Q3	$1.91M	Buy	+27,400	New	+$2.05M	﹤0.01%	2012
2022 Q3	–	Sell	-26,700	Closed	-$1.02M	–	5824
2022 Q2	$1.02M	Buy	+26,700	New	+$844K	﹤0.01%	2626
2021 Q1	–	Sell	-8,400	Closed	-$684K	–	6257
2020 Q4	$684K	Sell	8,400 -25,800	-75%	-$1.93M	﹤0.01%	3925
2020 Q3	$2.44M	Buy	34,200 +1,000	+3%	+$77.9K	﹤0.01%	2475
2020 Q2	$2.73M	Buy	+33,200	New	+$2.56M	﹤0.01%	2443

Other funds holding AXSM

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Citigroup's AXSM Position: Q1 2026 in Review

Citigroup reduced its Axsome Therapeutics (AXSM) stake by 9% in Q1 2026, selling an estimated $3.19M and leaving 185,658 shares worth $31.4M. The position accounts for 0.01% of the portfolio, ranked #850.

Citigroup first reported a position in AXSM in Q2 2016 and has held it in 34 quarters since. The position peaked at $37.3M in Q4 2025. 409 funds tracked by Wall St. Rank hold AXSM as of Q1 2026.

Citigroup held 185,658 shares of Axsome Therapeutics worth $31.4M as of Q1 2026.
Citigroup sold 18,446 Axsome Therapeutics shares in Q1 2026, an estimated $3.19M.
Axsome Therapeutics made up 0.01% of Citigroup's portfolio in Q1 2026, its #850 holding.
Citigroup first reported a position in Axsome Therapeutics in Q2 2016 and has held it in 34 quarters since.
Citigroup's Axsome Therapeutics position peaked at $37.3M in Q4 2025.
409 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q1 2026.

Based on Citigroup's 13F filing for Q1 2026, filed 11 May 2026.